Biomarkers Committee

 View Only
last person joined: 3 years ago 

The Biomarkers Committee provides expert guidance and insights on the state of the art in biomarker identification and application in the cancer immunotherapy setting, identifies current hurdles to further success and makes recommendations to the scientific community to more rapidly move the field forward, specifically pertaining to standardization and standards, validation of biomarkers identification and analysis, data and specimen sharing, and collaboration across disciplines by monitoring the advances in cancer Immunotherapy, emerging new technologies for measuring aspects of immunity and novel candidate biomarkers from early phase trials.

Holden T. Maecker, PhD
Stanford University

Sacha Gnjatic, PhD
Icahn School of Medicine at Mount Sinai

Alexandra Snyder, PhD